Radiolabeled antibody therapy in non-Hodgkins lymphoma: Radiation protection, isotope comparisons and quality of life issues

Cancer Treatment Reviews

Volumn 30, Issue 2, 2004, Pages 165-172

  Silverman, Daniel H ^a   Delpassand, Ebrahim S ^b   Torabi, Farzad ^b   Goy, Andre ^b   McLaughlin, Peter ^b   Murray, James L ^b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; IBRITUMOMAB TIUXETAN; RADIOISOTOPE; RITUXIMAB; TOSITUMOMAB I 131; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; RADIOPROTECTIVE AGENT;

ARTHRALGIA; BONE MARROW TOXICITY; CANCER PATIENT; CHILL; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DOSIMETRY; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; FAMILY; FATIGUE; FEVER; FLUSHING; GAMMA RADIATION; HEMATOLOGIC DISEASE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; ISOTOPE LABELING; MEDICAL STAFF; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; PRURITUS; QUALITY OF LIFE; RADIATION EXPOSURE; RADIATION HAZARD; RADIATION PROTECTION; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; RADIOLOGICAL PARAMETERS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; URTICARIA; VOMITING; COMPARATIVE STUDY; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; QUALITY OF LIFE; RADIATION-PROTECTIVE AGENTS; RADIOIMMUNOTHERAPY;

EID: 1642633148     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2003.07.006     Document Type: Article

References (19)

1. Hall P, Berg G, Bjelkengren G, et al. Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer 1992;50:886-90.
2. Holm LE, Hall P, Wiklund K, Lundell G, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991;83:1072-7.
3. Herbert JC, Eckelman WC, Neumann RD, Nuclear Medicine Diagnosis and Therapy. New York: Thieme Medical Publishers; 1996.
4. Wahl RL, Zasadyn KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the michigan phase I experience. J Nucl Med 1998;39(Suppl. 8):21S-7S.
5. Siegel A. Revised nuclear regulatory commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med 1998;39(Suppl. 8):28S-33S.
6. Reilly RM. Radioimmunotherapy of malignancies. Clin Pharm 1991;10(5):359-75.
7. Order SE, Stillwagon GB, Klein A, et al. Iodine 131 antiferritin, a new treatment modality in hepatoma: a radiation therapy oncology group study. J Clin Oncol 1985;3(12):1573-82.
8. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984;11(5):638-45.
9. Humm J. Dosimetric aspects of radiolabeled antibodies for tumour therapy. J Nucl Med 1986;27(9):1490-7.
10. Nourigat C, Badger CC, Bernstein ID. Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst 1990;82:47-50.
11. Stashenki P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125(4):1678-85.
12. 131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329(7):459-65.
13. Press OW, Farr AG, Borroz KI, et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49(17):4906-12.
14. Colcher D. Centralized radiolabeling of antibodies for radioimmunotherapy. J Nucl Med 1998;38(Suppl. 8):11S-3S.
15. 90Y-labeled B72.3 intraperitoneal administered in patients with ovarian cancer: effects of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 1999;5(5):953-61.
16. Murray JL. Factors for improving monoclonal antibody targeting. Diagnost Oncol 1992;2:234-41.
17. Kaminiski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14(7):1974-81.
18. Stajduhar KI, Neithercur J, Chu E, et al. Thyroid cancer: patients' experiences of receiving iodine-131 therapy. Oncol Nurs Forum 2000;27(8):1213-8.
19. 90Y-Zevalin (Yttrium-90 ibritumomab tiuxetan, IEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27(7):766-77.